

ASX Announcement

18 August 2025

ReNerve records first sale of deep dermal product range

ReNerve Limited (ASX, "ReNerve" or "the Company"), an Australian pioneering medical device company developing innovative products for peripheral nerve injury ("PNI") repair, is pleased to announce that it has successfully completed its first sale and clinical use of its new deep dermal tissue product.

ReNerve is complementing its nerve product offering in the USA market with the addition of a range of dermal and amniotic products. The initial case was a reconstructive plastic surgery repair case, aiming to repair scar tissue post breast reconstruction. The case did not require nerve repair, highlighting the benefit of the two new product lines in the ReNerve commercial product range, extending the target surgical cases for the Company with both new and existing customers.

"The first sale of the deep dermal product range is an important milestone for the Company. Although the initial sale and stocking order is not material relative to annual sales, it is an important next step for the company as it grows its commercial business. In addition, we anticipate bringing both our nerve conduit and amniotic product ranges to market in the US in the second half of this year, which should accelerate our revenue growth and complement our nerve cuff already in market" said **CEO Dr Julian Chick**.

ReNerve is progressing the commercialisation of the new deep dermal and amniotic tissue-based product ranges under a strategic partnership with Berkeley Biologics LLC announced on 2 June 2025. ReNerve is leveraging its eCOO technology, already proven through its Nervalign® Nerve Cuff, to develop and bring to market a range of nerve conduit products. The global dermal and amniotic tissue market is estimated to be worth around USD\$2.7 billion in 2024 and growing at around 12% CAGR¹, with these products used in a range of applications.

- ENDS -

This announcement has been approved for release by the Company's Board of Directors.

For further information and enquiries, please contact:

Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au

Matthew Wright
Investor & Media Relations
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

¹ MarketWide Research – Dermal and Amniotic tissue market report 2025-2032, Published 2025



About ReNerve Limited (ASX:RNV)

ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide.

Proven Clinical Success

ReNerve's first flagship product, the FDA-cleared **NervAlign® Nerve Cuff**, is already making a dramatic difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives.

Comprehensive Product Portfolio

ReNerve is advancing a complete suite of nerve repair solutions:

- **NervAlign® Nerve Cuff** – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery.
- **Deep Dermal tissue product** -- A unique deep dermal product used in the repair of reconstructive and cosmetic surgical cases.
- **Amniotic tissue product ranges** -- Three amniotic tissue product ranges used to aid the healing of wounds.
- **NervAlign® Nerve Conduit Range** – Next-generation nerve conduit leveraging advantages of eCOO technology in a material designed to facilitate nerve growth over short gaps between nerve ends.
- **NervAlign® Nerve Guide Matrix** – Eliminating the need for patients to undergo additional sural nerve harvesting.
- **NervAlign® Bionic Nerve** – Next-generation combination technology for the most challenging nerve repairs.

Market Leadership and Growth

With demonstrated market traction since the Company's 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching \$271k in sales. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US\$1.96 billion in 2024 and is projected to reach \$6.2 billion by 2031.²

² Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)

Vision and Values

We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.